Medicare.gov

Coronavirus disease 2019 (COVID-19) monoclonal antibody treatments

Medicare Part B (Medical Insurance)  covers FDA-authorized COVID-19 monoclonal antibody treatments and products, if all of these apply:

  • You tested positive for COVID-19.
  • You have a mild to moderate case of COVID-19.
  • You’re at high risk of progressing to a severe case of COVID-19 and/or at high risk of requiring hospitalization.

Your costs in Original Medicare

You pay nothing for a monoclonal antibody treatment in 2023. In 2024, Original Medicare will cover monoclonal antibody treatments if you have COVID-19 symptoms. 

Note

Certain monoclonal antibody products can protect you before you’re exposed to COVID-19. If you have Part B and your doctor decides this type of product could work for you (like if you have a weakened immune system), you pay nothing for the product when you get it from a Medicare provider or supplier.

What it is

If you test positive for COVID-19 and have mild to moderate symptoms, these treatments can help fight the disease and keep you out of the hospital. This treatment involves an infusion of monoclonal antibodies (specifically bamlanivimab, or casirivimab and imdevimab) to treat COVID-19. Health care providers can only give the infusions in certain settings.

Things to know

Medicare also covers COVID-19 diagnostic tests, COVID-19 antibody tests, and COVID-19 vaccines.

Related resources